Clinical Trial

A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of FB102 in patients with severe to very severe alopecia areata (AA).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-25.
Status change: Not Yet Recruiting → Recruiting 2025-11-17
Trial Details
NCT Number NCT07205159
Lead Sponsor Forte Biosciences, Inc.
Conditions Alopecia Areata
Enrollment 32 participants
Start Date 2025-10-23
Primary Completion 2027-03-10 (estimated)
Study Completion 2027-03-10 (estimated)
Updated on ClinicalTrials.gov 2025-11-20